MX2021009261A - Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1. - Google Patents

Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.

Info

Publication number
MX2021009261A
MX2021009261A MX2021009261A MX2021009261A MX2021009261A MX 2021009261 A MX2021009261 A MX 2021009261A MX 2021009261 A MX2021009261 A MX 2021009261A MX 2021009261 A MX2021009261 A MX 2021009261A MX 2021009261 A MX2021009261 A MX 2021009261A
Authority
MX
Mexico
Prior art keywords
immunomodulator
compound
fluorovinylbenzamide
isomer
formula
Prior art date
Application number
MX2021009261A
Other languages
English (en)
Inventor
Yang Zhang
Zhengxia Chen
Meibi Dai
Shuhui Chen
Jian Li
Yuanfeng Xia
Deheng Sun
Jian Zuo
Original Assignee
Shanghai Fosun Pharmaceutical Ind Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Fosun Pharmaceutical Ind Development Co Ltd filed Critical Shanghai Fosun Pharmaceutical Ind Development Co Ltd
Publication of MX2021009261A publication Critical patent/MX2021009261A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un inmunomodulador de PD-L1, y específicamente divulga un compuesto de fórmula (I) como inmunomodulador de PD-L1, una sal farmacéuticamente aceptable o un isómero del mismo. (ver fórmula).
MX2021009261A 2019-02-02 2020-02-03 Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1. MX2021009261A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910107946 2019-02-02
PCT/CN2020/074206 WO2020156568A1 (zh) 2019-02-02 2020-02-03 作为pd-l1免疫调节剂的氟乙烯基苯甲酰胺基化合物

Publications (1)

Publication Number Publication Date
MX2021009261A true MX2021009261A (es) 2021-11-12

Family

ID=71840372

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009261A MX2021009261A (es) 2019-02-02 2020-02-03 Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.

Country Status (9)

Country Link
US (1) US20220119368A1 (es)
EP (1) EP3919477A4 (es)
JP (1) JP7237169B2 (es)
KR (1) KR20210124328A (es)
CN (1) CN112752749B (es)
AU (1) AU2020214518B2 (es)
CA (1) CA3128282A1 (es)
MX (1) MX2021009261A (es)
WO (1) WO2020156568A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3919478A4 (en) * 2019-02-02 2022-12-07 Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. VINYLPYRIDINE CARBOXAMIDE COMPOUND USEFUL AS A PD-L1 IMMUNOMODULATOR

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
EP1401831A1 (en) * 2001-07-03 2004-03-31 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
KR20050004214A (ko) * 2002-05-31 2005-01-12 에자이 가부시키가이샤 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물
EP3333157B1 (en) * 2015-08-07 2020-12-23 Harbin Zhenbao Pharmaceutical Co., Ltd. Vinyl compounds as fgfr and vegfr inhibitors
EP3919478A4 (en) * 2019-02-02 2022-12-07 Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. VINYLPYRIDINE CARBOXAMIDE COMPOUND USEFUL AS A PD-L1 IMMUNOMODULATOR

Also Published As

Publication number Publication date
AU2020214518A1 (en) 2021-08-26
CN112752749B (zh) 2021-07-16
WO2020156568A1 (zh) 2020-08-06
AU2020214518B2 (en) 2022-12-15
CN112752749A (zh) 2021-05-04
US20220119368A1 (en) 2022-04-21
EP3919477A4 (en) 2022-12-07
KR20210124328A (ko) 2021-10-14
CA3128282A1 (en) 2020-08-06
JP7237169B2 (ja) 2023-03-10
JP2022521673A (ja) 2022-04-12
EP3919477A1 (en) 2021-12-08

Similar Documents

Publication Publication Date Title
PH12018501099A1 (en) Novel biphenyl compound or salt thereof
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
PH12020500673A1 (en) Compounds
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
MX2019014104A (es) Compuesto novedoso de bifenilo o sal del mismo.
AU2020317609A8 (en) Novel heteroaryl-triazole compounds as pesticides
EA201792021A1 (ru) Ингибитор jak
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
ZA202201503B (en) Urea compound for antagonizing lpa1 receptor
CA3139411A1 (en) Novel peptide compound or pharmaceutically acceptable salt thereof
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
MX2022006653A (es) Compuestos para modular la actividad de fxr y usos de los mismos.
PH12019550154A1 (en) Azetidine derivative
MY193239A (en) Novel b-lactamase inhibitors
MX2021001904A (es) Formas solidas de benzoxaborol sustituido y composiciones de las mismas.
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.
WO2020139971A3 (en) Methods for making dimeric naphthalimides and solid state forms of the same
MX2020004974A (es) Uso del compuesto de carbamato para reducir o tratar trastornos del desarrollo que incluyen sindrome x fragil, sindrome de angelman o sindrome de rett.
MX2022006984A (es) Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina.
MX2022002720A (es) Inhibidor de magl, procedimiento de preparacion y uso del mismo.